Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score-Reference-Cited by-同舟云学术

Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score

Published:2021-02 Issue: Volume: Page:
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Pérez de Llano Luis,Dávila Ignacio,Martínez-Moragón Eva,Domínguez-Ortega Javier,Almonacid Carlos,Colás Carlos,García-Rivero Juan Luis,Carmona Loreto,García de Yébenes María Jesús,Cosío Borja G.,Torrego Alfons,Mena Alicia Habernau,Viña Antolín López,Arrondo Antonio Parra,Crespo Astrid,Santana Aythamy Henrquez,Cisneros Carolina,Picado César,Domingo Cristian,Antolin Dario,Álvarez Francisco,Soto Gregorio,Ercoreca Ignacio Antepara,Ojanguren Íñigo,Bobolea Irina,Urrutia Isabel,Moguel Ismael García,Dominguez Joaquín Sastre,Rivera José María Olaguibel,Chicote José María Vega,Serrano José,Miralles Juan Carlos,Romero Julio Delgado,Prado Manuel Jorge Rial,Mosteiro Mar,Blanco Marina,Perpiñá Miguel,Mozo Paloma Campo,Sanz Pilar Barranco,Contreras Remedios Cardenas,Gancedo Santiago Quirce,De Cabrës Valentina Gutiérrez Vall,Plaza Vicente,Gallardo Victoria García,Muñoz Xavi

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference17 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014

2. Severe and non-severe asthma in the community: a large electronic data base analysis;Varsano;Respir Med,2017

3. Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain;Quirce;J Investig Allergol Clin Immunol,2011

4. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study;Pérez de Llano;Respir Med,2019

5. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma;Agache;Allergy,2020

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma;The Journal of Allergy and Clinical Immunology: In Practice;2024-09

2. Spanish Consensus on Remission in Asthma (REMAS);Archivos de Bronconeumología;2024-08

3. Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis;Journal of Clinical Medicine;2024-07-20

4. Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort;Allergy;2024-06-22

5. Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study;Journal of Asthma;2024-05-09